Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 bioequivalence study of HTX-019 intravenous (IV) injection compared to oral Aprepitant in patients with Postoperative nausea and vomiting (PONV)

Next Previous
Trial Profile

A phase 1 bioequivalence study of HTX-019 intravenous (IV) injection compared to oral Aprepitant in patients with Postoperative nausea and vomiting (PONV)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aprepitant (Primary) ; Aprepitant
  • Indications Postoperative nausea and vomiting
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 26 Oct 2022 Results assessing Bioavailability Study Of Htx-019 Intravenous Injection Compared With Aprepitant Oral Capsules presented at the ANESTHESIOLOGY 2022 Annual Meeting of the American Society of Anesthesiologists
  • 16 Sep 2022 According to Heron Therapeutics media release, the U.S. Food and Drug Administration (FDA) has approved APONVIE (aprepitant) injectable emulsion, for intravenous use for the prevention of postoperative nausea and vomiting (PONV) in adults.
  • 28 Feb 2022 According to a Heron Therapeutics media release, NDA Submission for HTX-019 for prevention of PONV in adults accepted by FDA with a PDUFA goal date of September 17, 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top